Terminology Service for NFDI4Health
All terms in NCIT
| Label | Id | Description |
|---|---|---|
| BF-200 Gel Formulation | NCIT_C131905 | [A topical nanoemulsion-based gel formulation containing 5-aminolevulinic acid (ALA), a metabolic precursor of the photosensitizer protoporphyrin IX, with a potential application for enhanced photodynamic therapy (PDT) for various precancerous and malignant skin lesions. After topical administration of a thick layer of the ALA-based BF-200 gel formulation to the affected area, ALA penetrates the skin and is intracellularly converted to protoporphyrin IX (PpIX). Exposure of PpIX to the proper excitation wavelength of light generates singlet oxygen molecules, resulting in a local cytotoxic effect.] |
| Photosensitizing Agent | NCIT_C1420 | [Any pharmaceutical that is administered as an inactive precursor that can be converted to its pharmacologically active form through exposure to ultraviolet radiation or sunlight.] |
| EBV-Positive Mucocutaneous Ulcer | NCIT_C131906 | [A rare Epstein-Barr virus-positive B-cell lymphoproliferative disorder which presents as an ulcerative mucocutaneous lesion. It is associated with immune suppression, including age-related and drug-induced immunosuppression.] |
| EBV-Related Lymphoproliferative Disorder | NCIT_C159717 | [A lymphoproliferative disorder associated with Epstein-Barr virus. This category includes, but is not limited to, Burkitt lymphoma, classic Hodgkin lymphoma, and lymphomas arising in immunocompromised individuals.] |
| Atypical Lymphoproliferative Disorder | NCIT_C7764 | [A lymphoproliferative disorder characterized by the presence of an atypical lymphocytic infiltrate.] |
| Anti-TIGIT Monoclonal Antibody BMS-986207 | NCIT_C131907 | [A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody BMS-986207 binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.] |
| Anti-TIGIT Monoclonal Antibody | NCIT_C134787 | [Any monoclonal antibody against TIGIT.] |
| LSD1 Inhibitor RO7051790 | NCIT_C131908 | [An orally available inhibitor of lysine specific histone demethylase 1 (KDM1A; LSD1), with potential antineoplastic activity. Upon administration, RO7051790 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9, which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in in the regulation of gene expression, tumor cell growth and survival.] |
| EGFR T790M Antagonist BPI-15086 | NCIT_C131909 | [An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. EGFR T790M antagonist BPI-15086 specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.] |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | NCIT_C2167 | [Any tyrosine kinase inhibitor that targets the activity of the epidermal growth factor receptor (EGFR) tyrosine kinase. Inhibition of epidermal growth factor receptor tyrosine kinase may inhibit the growth of epidermal-lineage tumor cells, especially those that overexpress epidermal growth factor receptor.] |
| ADCS-ADL MCI - Subscore for Items 1 to 3 | NCIT_C106970 | [Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 1. (Range = 0-10).] |
| Insular Pattern | NCIT_C35916 | |
| Alveolar Pattern | NCIT_C35917 | |
| Organoid Pattern | NCIT_C35918 | |
| Cylindromatous Pattern | NCIT_C35919 | |
| Pseudopapillary Pattern | NCIT_C35912 | [A morphologic finding indicating the presence of poorly cohesive neoplastic cells arranged around fibrovascular cores in a tissue sample.] |
| Trabecular Pattern | NCIT_C35913 | [A microscopic finding indicating that the neoplastic cells are arranged in trabeculae in a tumor sample.] |
| Gyriform Trabecular Pattern | NCIT_C35914 | |
| Macrotrabecular Pattern | NCIT_C35915 | |
| Antoni B Pattern | NCIT_C35910 |